These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
333 related articles for article (PubMed ID: 12810652)
21. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Nakatomi K; Yoshikawa M; Oka M; Ikegami Y; Hayasaka S; Sano K; Shiozawa K; Kawabata S; Soda H; Ishikawa T; Tanabe S; Kohno S Biochem Biophys Res Commun; 2001 Nov; 288(4):827-32. PubMed ID: 11688982 [TBL] [Abstract][Full Text] [Related]
22. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Yang CH; Schneider E; Kuo ML; Volk EL; Rocchi E; Chen YC Biochem Pharmacol; 2000 Sep; 60(6):831-7. PubMed ID: 10930538 [TBL] [Abstract][Full Text] [Related]
23. Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines. Takahata T; Ookawa K; Suto K; Tanaka M; Yano H; Nakashima O; Kojiro M; Tamura Y; Tateishi T; Sakata Y; Fukuda S Basic Clin Pharmacol Toxicol; 2008 Apr; 102(4):399-407. PubMed ID: 18248513 [TBL] [Abstract][Full Text] [Related]
24. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). van den Heuvel-Eibrink MM; Wiemer EA; Prins A; Meijerink JP; Vossebeld PJ; van der Holt B; Pieters R; Sonneveld P Leukemia; 2002 May; 16(5):833-9. PubMed ID: 11986944 [TBL] [Abstract][Full Text] [Related]
25. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658 [TBL] [Abstract][Full Text] [Related]
26. Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer. Kovalev AA; Tsvetaeva DA; Grudinskaja TV Exp Oncol; 2013 Dec; 35(4):287-90. PubMed ID: 24382439 [TBL] [Abstract][Full Text] [Related]
27. Interactions of cyclosporin a with breast cancer resistance protein. Xia CQ; Liu N; Miwa GT; Gan LS Drug Metab Dispos; 2007 Apr; 35(4):576-82. PubMed ID: 17220244 [TBL] [Abstract][Full Text] [Related]
28. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Yoshikawa M; Ikegami Y; Hayasaka S; Ishii K; Ito A; Sano K; Suzuki T; Togawa T; Yoshida H; Soda H; Oka M; Kohno S; Sawada S; Ishikawa T; Tanabe S Int J Cancer; 2004 Jul; 110(6):921-7. PubMed ID: 15170677 [TBL] [Abstract][Full Text] [Related]
29. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance. Su Y; Lee SH; Sinko PJ Eur J Pharm Sci; 2006 Oct; 29(2):102-10. PubMed ID: 16844360 [TBL] [Abstract][Full Text] [Related]
30. Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. Wang X; Nitanda T; Shi M; Okamoto M; Furukawa T; Sugimoto Y; Akiyama S; Baba M Biochem Pharmacol; 2004 Oct; 68(7):1363-70. PubMed ID: 15345326 [TBL] [Abstract][Full Text] [Related]
31. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923 [TBL] [Abstract][Full Text] [Related]
32. Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan. Gounder MK; Nazar AS; Saleem A; Pungaliya P; Kulkarni D; Versace R; Rubin EH Invest New Drugs; 2008 Jun; 26(3):205-13. PubMed ID: 17943230 [TBL] [Abstract][Full Text] [Related]
33. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Allen JD; Van Dort SC; Buitelaar M; van Tellingen O; Schinkel AH Cancer Res; 2003 Mar; 63(6):1339-44. PubMed ID: 12649196 [TBL] [Abstract][Full Text] [Related]
34. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043 [TBL] [Abstract][Full Text] [Related]
35. Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells. Ishikawa T; Ikegami Y; Sano K; Nakagawa H; Sawada S Curr Pharm Des; 2006; 12(3):313-25. PubMed ID: 16454746 [TBL] [Abstract][Full Text] [Related]
36. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Imai Y; Nakane M; Kage K; Tsukahara S; Ishikawa E; Tsuruo T; Miki Y; Sugimoto Y Mol Cancer Ther; 2002 Jun; 1(8):611-6. PubMed ID: 12479221 [TBL] [Abstract][Full Text] [Related]
37. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Schellens JH; Maliepaard M; Scheper RJ; Scheffer GL; Jonker JW; Smit JW; Beijnen JH; Schinkel AH Ann N Y Acad Sci; 2000; 922():188-94. PubMed ID: 11193894 [TBL] [Abstract][Full Text] [Related]
38. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Shepard RL; Cao J; Starling JJ; Dantzig AH Int J Cancer; 2003 Jan; 103(1):121-5. PubMed ID: 12455064 [TBL] [Abstract][Full Text] [Related]
39. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Doyle L; Ross DD Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842 [TBL] [Abstract][Full Text] [Related]
40. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Volk EL; Farley KM; Wu Y; Li F; Robey RW; Schneider E Cancer Res; 2002 Sep; 62(17):5035-40. PubMed ID: 12208758 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]